President Biden announced Monday that the United States will export 20 million doses of the Pfizer-BioNTech, Moderna, and Johnson & Johnson COVID-19 vaccines by the end of June. Those doses are on top of the 60 million doses of the vaccine developed by the University of Oxford and AstraZeneca already earmarked for export.
The AstraZeneca vaccine has not received authorization from the Food and Drug Administration, so the U.S. wouldn't be able to distribute the doses produced in the country anyway, but the latest development is significant because the other companies' shots are in use domestically.
An anonymous Biden administration official told Bloomberg the measure is only a first step, and, as the vaccination rate plateaus in the U.S., the White House will increasingly turn its attention to helping curb the coronavirus pandemic abroad. The pivot comes as the global discrepancy in vaccinations has become more glaring — many lower-income countries are struggling to secure supplies even as the virus surges in many pockets of the world.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
It's not yet clear where exactly the exported vaccines will go, or how the U.S. will decide which countries get them, but White House Press Secretary Jen Psaki said the criteria should become available soon. One thing Biden did clarify in his comments is that the U.S. won't use vaccines to secure favors from other countries. Read more at Bloomberg.
Create an account with the same email registered to your subscription to unlock access.